// IP Marketing video - START// IP Marketing video - END

Meningitis vaccine licensed for use in Europe

Meningitis vaccine licensed for use in Europe

PanARMENIAN.Net - A vaccine to protect children against one of the most common and deadly forms of meningitis has been licensed for use in Europe, BBC News reported.

The Bexsero vaccine licensed by the European Commission is the first to cover meningococcal B meningitis - until now vaccines had protected against only some of the bacterial types involved.

About 1,870 people contract meningitis B each year and one in 10 die.

About a quarter of all survivors of meningitis B are left with life altering after-effects, such as brain damage or limb loss. Children under the age of five are the most at risk from the bacterial infection, which leads to inflammation of the brain and spinal cord.

Experts say the jab is likely to be effective against 73% of the different variations of meningitis B.

A vaccine against the less common meningitis C has been administered since 1999 and is now widely given to babies in the first year of their life.

It has led to a large fall in the number of cases in people under the age of 20.

 Top stories
Journalist and writer Andrei Khvostov was the first to express such an idea which was supported by other Estonian writers too.
Sahakyan said that the newly-established company cann't consider Armenia as a potential market for the comping 10 years.
Tis year's Yerevan Half Marathon, slated for October 15, promises to be the best and largest running event in Armenia.
Armenia might be both one of the oldest and one of the youngest nations in the history of beer making, The Smithsonian said in an article.
Partner news